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1. Introduction 
 The tumor microenvironment plays an important role in providing a niche to nurture the growth of 
cancer cells [1]. Recently, stromal cells, growth factors, cytokines, and ECM proteins in the tumor 
microenvironment have been implicated in promoting resistance to chemotherapeutics as well [2, 3]. 
Specifically, certain stromal growth factors mediate cell proliferation in the presence of otherwise powerful 
chemotherapeutic drugs. For example, hepatocyte growth factor (HGF) imparts resistance to vemurafenib 
in melanoma [4, 5], and TGF-β induces the expansion of cancer stem-like cells, which are responsible for 
chemotherapy-resistance and relapses [6]. These growth factors are generally thought to be released by 
local stromal fibroblasts, which upon DNA-damage from treatments with a combination of mitoxantrone 
and docetaxel, or radiation stimulate prostate cancer cell proliferation and invasion through β-catenin 
signaling [7]. In addition to soluble growth factors, a change in adhesive ECM proteins in the tissue can 
confer resistance to chemotherapeutics via integrin-mediated signaling [8-11]. 
 This evolution in the microenvironment during tumor progression is mediated by stromal 
fibroblasts, which differentiate into myofibroblasts [12] and cancer-associated fibroblasts (CAFs) [13], and 
remodel the ECM by breaking down the basement membrane and depositing fibril forming collagens [14-
16]. The increase in crosslinked fibrous collagens results in tissue stiffening [17, 18], which stimulates cell 
proliferation [17, 19], invasion and intravasation [20, 21], disrupts cell-cell adhesion [22], and alters cell 
sensitivity to growth factors [23], while simultaneously limiting the diffusion of therapeutic agents into the 
tumor [24]. 
We hypothesized that these mechanochemical changes in the ECM during tumor progression 
may induce drug resistance in carcinoma. Testing this hypothesis required that we develop a new drug 
testing platform that included not only human cell lines and appropriate growth factors, but also tailored 
control over integrin-binding and ECM stiffness.  Many groups are spurring the development of novel cell 
culture platforms for more rational and predictive drug discovery [25-27], however, we found that existing 
systems are either cumbersome to use, or have limited adaptability. In response, we adapted our 
previously published PEG-PC hydrogel system, an easy to use biomaterial, which is optically transparent, 
forms gels ranging from 1-10,000 kPa in Young's modulus, can be coupled with any protein or peptide of 
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interest, and rapidly polymerizes within 96-well plates [28].  This new method allowed us to quantify drug 
response in a high-throughput manner across a range of stiffness and integrin-binding conditions.  
The role of stiffness in regulating drug response was explored by Schrader et al., who observed a 
reduction in apoptosis of cells on stiff substrates when treated with cisplatin [29]. Also, Zustiak et al. 
reported cell line-dependent stiffness sensitivity to paclitaxel [30].  Sorafenib was developed as a Raf 
kinase inhibitor [31], and unlike these previously tested drugs, there is no obvious link between this 
signaling pathway and ECM stiffness. Phosphorylation of ERK, a downstream effector of Raf kinase, has 
been implicated in controlling cell proliferation during ECM stiffening [19, 32], so we hypothesized that 
sorafenib efficacy could be hampered in stiff environments, contributing at least partially to sorafenib's 
modest clinical efficacy [33]. 
To capture the evolution of the tumor microenvironment during disease progression, we formed 
hydrogel environments with a range of stiffnesses, including either basement membrane-like ECM 
proteins [34], or a collagen-rich inflammatory ECM [21]. We examined whether stiff environments 
protected carcinoma cells from sorafenib treatment, and if this drug resistance was mediated by the 
canonical Rho-ROCK and β1 integrin signaling pathways. Motivated by a targeted phospho-proteomic 
screen, we also quantified the role of ERK, Akt, JNK and p38 signaling during cell response to sorafenib 
on stiff substrates. Our results demonstrate the utility of our tunable, high-throughput PEG-PC biomaterial 
platform in drug screening, and identify an exciting new mechanism to increase the efficacy of sorafenib 
in stiff tumor environments.   
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2. Materials and methods 
2.1. Cell culture 
All supplies were purchased from Life Technologies (Carlsbad, CA) unless otherwise noted. 
Human breast cancer cell lines (MDA-MB-231, BT549, and SkBr3) were generous gifts from Dr. Shannon 
Hughes at the Massachusetts Institute of Technology, and were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) 
at 37ºC and 5% CO2.  Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American Type Culture 
Collection, Manassas, VA) were cultured in modified Eagle's medium (MEM) supplemented with 10% 
FBS and 1% P/S at 37ºC and 5% CO2. 
2.2. 96-well hydrogel platform 
Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific, Sunnyvale, CA) were 
plasma treated (Harrick Plasma, Ithaca, NY) and subsequently methacrylate-silanized with 2 vol% 3-
(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in 95% ethanol (adjusted to pH 5.0 
with glacial acetic acid) for 5 min, washed 3 times with 100% ethanol, and dried at 40 °C for 30 min. 
PEGDMA (Mn 750, Sigma-Aldrich), from 0.6-9.1 wt%, was combined with 17 wt% 2-methacryloyloxyethyl 
phosphorylcholine (PC) (Sigma-Aldrich) in phosphate buffered saline (PBS). These PEGDMA crosslinker 
concentrations tune the Young's moduli of the resulting gels from 6 to 400 kPa [28]. Solutions were 
sterilized with a 0.2 μm syringe filter (Thermo Fisher Scientific, Waltham, MA) and degassed by nitrogen 
sparging for 30s. Free-radical polymerization was induced by addition of 0.05 wt% ammonium persulfate 
(APS) and 0.125 vol% tetramethylethylenediamine (TEMED, Bio-Rad Laboratories, Hercules, CA). 
Hydrogels of 40 μL per well in the 96-well plates were polymerized under nitrogen for 10 min.  
Post-polymerization, hydrogels were allowed to swell for 24 hours in PBS, then treated with 100 
μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 HEPES buffer) under UV light for 
20 min, rinsed twice with HEPES buffer, and followed immediately by incubation with protein mixtures 
overnight. ECM protein mixtures were defined as either “basement membrane” composed of 46% human 
collagen IV (Neuromics, Edina, MN), 46% human fibronectin (EMD Millipore, Billerica, MA), and 8% 
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mouse laminin at 5 μg/cm2, buffered in pH 7.0 PBS, or “collagen rich” composed of 65% rat tail collagen I, 
33% human collagen III (FibroGen, San Francisco, CA), and 2% fibronectin at 5 μg/cm2, buffered in pH 
3.8 PBS. Post-protein coupling, the gels were rinsed twice with PBS, UV-sterilized for 1 h, and rinsed with 
sterile medium before cell seeding.  
2.3. Quantification of drug resistance 
Cells were seeded onto gel surfaces at a density of 31,000 cells/cm2 in serum-free medium 
supplemented with 20 ng/mL of platelet-derived growth factor (PDGF-BB, eBioscience, San Diego, CA) 
and 20 ng/mL of epidermal growth factor (EGF, R&D Systems, Minneapolis, MN). After 24 h, cells were 
treated with sorafenib (LC Laboratories, Woburn, MA) from 0 to 120 μM, diluted in growth factor-
supplemented serum-free medium. After 24 h, we measured cell proliferation with CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI) at 490 nm (BioTek ELx800 microplate 
reader, BioTek, Winooski, VT). The concentration of sorafenib that reduced cell proliferation by 50% (IC-
50) was calculated with Prism v5.04 (GraphPad Software, La Jolla, CA). In some experiments, sorafenib 
was also co-administered with: an anti-β1 integrin antibody (clone P5D2, R&D Systems, 0.5 μg/mL), 
p160ROCK inhibitor (Y-27632, R&D Systems, 10 μM), EGF receptor (EGFR) inhibitor (AG1478, AG 
Scientific, San Diego, CA, 1 μM), JNK inhibitor (SP600125, LC Laboratories, 20 μM), p38 inhibitor 
(BIRB796, LC Laboratories, 1 μM), or ERK inhibitor (FR180204, Sigma-Aldrich, 20 μM). Dimethyl 
sulfoxide (Sigma-Aldrich) was used as a vehicle control in all experiments. We also verified that cell 
proliferation measurements approximately linearly correlated to cell count (Suppl. Fig. 1). 
2.4. Immunofluorescent imaging 
18 mm glass coverslips (Thermo Fisher Scientific, Waltham, MA) were plasma treated, 
methacrylate-silanized, and dried at 120 °C for 15 min. 80 μL PEG-PC hydrogels were polymerized with 
APS and TEMED between a methacrylated-silanized coverslip and an untreated coverslip for 20 min on 
the bench. After polymerization, the hydrogels were allowed to swell in PBS, and the non-treated 
coverslips were removed easily with fine forceps.  Swollen gels on coverslips were transferred to 12-well 
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tissue culture dishes, coupled with protein mixtures as described above, rinsed 3 times with PBS, and 
UV-sterilized for 1 h prior to cell seeding. 
Cells were seeded at a density of 10,000 cells/cm2 in growth factor-supplemented serum-free 
medium and allowed to adhere for 24 hours.  Cells were rinsed three times with warm PBS, fixed with 4% 
formaldehyde, permeabilized with Tris-buffered saline (TBS) containing 0.5% Triton X-100 (Promega), 
and blocked with AbDil (2 wt.% BSA in TBS with 0.1% Triton X-100, TBS-T). F-actin was labeled with 
Alexa Fluor 555-conjugated phalloidin for 1 h. Vinculin was labeled with a monoclonal mouse anti-vinculin 
antibody (Sigma-Aldrich) for 1 h, followed by an anti-mouse FITC secondary antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA) for 1 h. Cell nuclei were labeled with DAPI (MP 
Biomedicals, Santa Ana, CA) for 5 min. Each sample was treated with ProLong Gold antifade reagent for 
5 min before imaging on a Zeiss Axio Observer Z1 microscope with a 63x oil immersion objective (Carl 
Zeiss AG, Oberkochen, Germany), and images were compiled in ImageJ (NIH, Bethesda, MD). 
2.5. Multiplex phospho-protein quantification 
MDA-MB-231 cells ('231s') were seeded at 50,000 cells/cm2 on 6 and 400 kPa 18 mm diameter 
coverslip-mounted gels in 12-well plates. Immediately after seeding, at 0 min, 30 min, 1 h, 2 h, 4 h, 6 h, 
and 24 h time points, coverslips were transferred to a new 12-well plate on ice, the gels were washed 
once with ice-cold Bioplex cell wash buffer (Bio-Rad, Hercules, CA), and lysed with ice-cold lysis buffer 
(Bioplex cell lysis buffer, Bio-Rad) containing protease (EDTA-free Protease Inhibitor Cocktail Tablets, 
Roche, Indianapolis, IN) and phosphatase (2x phosphatase inhibitors cocktail-II, Boston Bioproducts, 
Boston, MA) inhibitors. Separately, cells were allowed to adhere for 24 hours, treated with sorafenib, and 
lysates were collected at 0 min, 1 h, 5 h, 15 h, and 24 h time points after sorafenib treatment. Total 
protein concentration was quantified with a BCA protein assay (Thermo Scientific, Rockford, IL). Lysate 
concentrations were adjusted to 100 μg/mL, and the phosphorylation levels of ERK1/2, Akt, JNK, and p38 
were quantified with a MAGPIX (Luminex, Austin, TX) with Bio-Plex Pro™ phospho-ERK1/2, phospho-
Akt, phospho-JNK, and phopho-p38 magnetic beads (Bio-Rad), according to the manufacturer 
instructions. 
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2.6. Statistical analysis 
A one-way analysis of variance (ANOVA) with a Tukey post-test was performed with Prism v5.04 
(GraphPad Software). Data are reported as mean ± standard error. p ≤ 0.05 is denoted with *, ≤ 0.01 with 
**, and ≤ 0.001 with ***. 
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3. Results 
3.1. Carcinoma cell response to sorafenib on PEG-PC hydrogels 
We created a high-throughput biomaterial platform to rapidly assay cell responses to 
chemotherapeutic drugs in different mechanochemical environments (Fig. 1). In particular, we focused on 
how these changes perturbed the efficacy of sorafenib, a Raf kinase inhibitor approved for thyroid, kidney 
and liver cancer, but which has had limited clinical success [33, 35, 36].  One potential cause of 
chemotherapy evasion by carcinoma cells might be the stiffening of the tumor environment itself, and so 
we quantified the responses of a liver cancer cell line and three breast cancer cell lines to sorafenib on 
PEG-PC of increasing stiffness.  In all cell lines, we consistently observed a significant increase in 
sorafenib IC-50, the concentration at which the proliferation was dampened by half, with increasing 
substrate stiffness (Figs. 2A-B).  We observed this phenomenon on both the basement membrane-like 
ECM (Fig. 2A), and the collagen-rich ECM (Fig. 2B), demonstrating that this stiffness-induced drug 
resistance is maintained even with alterations in integrin binding. Two of the breast cancer cell lines we 
tested, the SkBr3s and 231s, were the most drug resistant cell lines on the basement membrane ECM 
(Fig. 2A). When we normalized the IC-50s within each cell line to the softest condition, we observed that 
these two cell lines also showed the most stiffness-induced resistance to sorafenib, with 3.7 and 3 fold 
increases in IC-50 on the stiffest gels when compared to the softest condition, respectively (Suppl. Fig. 
2A). On the collagen-rich mixture, again the 231 and SkBr3s were the most drug resistant cell lines (Fig. 
2B), but, interestingly, the HEP3B cell line was the most stiffness sensitive (Suppl. Fig. 2B). Altogether, on 
the collagen-rich ECM, the SkBr3 and 231 cell lines are more sorafenib resistant across all gel conditions. 
Stiffness increases their sorafenib resistance, but they appear less stiffness sensitive than the HEP3Bs 
because the HEP3Bs are, overall, less resistant to sorafenib. 
Neither initial cell adhesion to the gels, nor proliferation at 24 hours showed the same consistent 
trends as drug resistance, ruling them out as significant contributors to sorafenib resistance (Figs. 2C-D, 
Suppl. Fig. 3). We also cultured the 231 cells for five days prior to sorafenib treatment and found that the 
cells responded to sorafenib in the same manner as compared to dosing 24 hours post-seeding, but with 
larger IC-50s due to cell proliferation in the days prior to drug treatment (Fig. 2E). This result 
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demonstrates that the observed stiffness-mediated drug resistance is maintained at longer time points of 
culture. 
3.2. Cytoskeletal tension and sorafenib resistance  
Given the known role of substrate stiffness in influencing cell proliferation via the canonical Rho-
ROCK pathway [19, 32], we hypothesized that intracellular tension was the most probable mechanism by 
which increasing stiffness protected cells from sorafenib. We quantified cell area and imaged F-actin 
organization in response to increasing substrate stiffness for the two most drug resistant cell lines (231 
and SkBr3, Figs. 3A-D). Interestingly, on the collagen-rich ECM, cell spread area had a biphasic 
dependence on substrate stiffness, whereas cell spread area increased with stiffness on the basement 
membrane proteins. This result does not match the observed drug resistance results (compare Figs. 3B 
and D with Figs. 2A-B), and implies that intracellular tension does not exclusively explain the observed 
stiffness-mediated resistance on collagen-rich ECM.  Figs. 3A-D also demonstrate that integrin binding 
(via ECM proteins) influences the sensitivity of cell area to substrate stiffness. 
We further examined the potential role of intracellular tension in mediating stiffness-induced 
sorafenib resistance via ROCK activity. ROCK is a downstream effector of RhoA, a GTPase that 
regulates cell contractility and actin stress fiber formation [37]. We co-administered sorafenib with a 
ROCK inhibitor (Y27632) in both the 231 and SkBr3 cell lines on the collagen-rich ECM (Figs. 3E-F). 
When compared to the sorafenib alone condition (black lines), ROCK inhibition (red lines) dampened 
sorafenib resistance across all moduli, except for the stiffest condition; however, even in the presence of 
ROCK inhibitor, the IC-50s still increased with stiffness in both cell lines. Going further, we attempted to 
block cell adhesion to the collagen-rich ECM by co-administering sorafenib with a blocking antibody to the 
β1 integrin subunit (blue lines). Blocking β1 integrin was significantly effective in the 231 cells at all 
stiffnesses, but had no effect on sorafenib resistance in the SkBr3s, perhaps implying that SkBr3s can 
survive sorafenib treatment in low adhesive environments. Finally, we treated cells with an inhibitor to 
EGFR, given the known role EGFR activation in promoting resistance of several HCC cell lines to 
sorafenib [38], and given the fact that all these experiments are supplemented with EGF. EGFR inhibition 
(green lines) increased the efficacy of sorafenib modestly in both cell lines, but the trend of stiffness-
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induced drug resistance remained. Taken together, neither ROCK nor EGFR appears to regulate 
stiffness-mediated sorafenib resistance; however, β1 integrin antibody may be a candidate for co-
treatment with sorafenib in triple negative breast cancer (the subtype of the 231 cell line), but not HER2 
overexpressing breast cancer (SkBr3 subtype).  
3.3. Signaling pathways activated during ECM stiffening 
Given that β1 integrin antibody was the only effective co-treatment with sorafenib in the 231 cells, 
we investigated a subset of candidate signaling pathways, downstream of β1, which might be interfering 
with sorafenib efficacy. We used a multi-plex MAGPix system to quantify the phosphorylation of three 
members of the MAPK family (ERK1/2, JNK, p38), and Akt of the PI3K pathway at multiple time points 
post-adhesion to the softest and stiffest substrates tested in the 231 cell line (Figs. 4A-D). On both the 
collagen-rich and basement membrane ECMs, we observed an early peak in phosphorylation of ERK1/2 
and Akt post-adhesion, but there was no difference when comparing between the soft and stiff gel 
conditions. JNK phosphorylation was delayed on the basement membrane ECM when compared to the 
collagen rich ECM, and the activity of JNK and p38 was higher on the stiffer gel at all time points on the 
collagen-rich ECM. Therefore, changes in JNK signaling could partially explain differences in cell 
behavior on the two protein mixtures, and both JNK and p38 are promising candidates to explain 
sorafenib resistance on stiff substrates. 
3.4. Combinatorial treatment of a JNK inhibitor and sorafenib on stiff substrates 
To determine whether sorafenib treatment perturbed the activity of these signaling proteins, we 
allowed 231 cells to adhere to the two stiffness gels coupled with collagen-rich ECM for 24 hours, and 
performed the MAGPix assay at various time points directly following a 15 µM sorafenib treatment. Upon 
sorafenib treatment, ERK1/2 phosphorylation on the stiff substrate remained significantly higher than that 
on the softer gel at early time points post-dosing (Fig. 5A). Akt phosphorylation also peaked in the first 
hour after sorafenib treatment; however, there was no difference in Akt phosphorylation between the soft 
and stiff substrates, which further confirmed that Akt signaling was not involved in stiffness-mediated drug 
resistance (Fig. 5B). The observed peak in Akt might be due to the ability of Ras to mediate signaling 
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through PI3K/Akt pathway [39], while sorafenib inhibits the Ras/Raf/MEK/ERK pathway. JNK 
phosphorylation was highest on the stiff substrate, and, unlike ERK and Akt, did not change over time 
(Fig. 5C). Sorafenib treatment also reduced the stiffness sensitivity of p38 phosphorylation (Fig. 5D).  
When considering the results in Figures 4 and 5 together, ERK, p38, and JNK were all potential 
candidates for involvement in stiffness-mediated sorafenib resistance. We co-administered sorafenib with 
inhibitors to each of these molecules (Fig. 5E), and found that JNK inhibition (blue line) both significantly 
increased sorafenib efficacy, and eliminated the impact of substrate stiffness. In hindsight, this result 
could have been anticipated, as JNK was the only signaling molecule both enhanced by substrate 
stiffness during cell adhesion (Fig. 4C), and unaffected by sorafenib treatment (Fig. 5C). With an 
expected synergistic effect in mind, we then co-administered sorafenib with JNK inhibitor, and either ERK 
or p38 inhibitors (Fig. 5F). Strikingly, we found that combining either p38 or ERK inhibitors alongside the 
JNK inhibitor and sorafenib treatment reversed the effect of co-administering the JNK inhibitor alone.   
4. Discussion 
Several groups have demonstrated a link between substrate stiffness and cell proliferation across 
a variety of cell types [30, 40-43], and many of these studies have linked stiffness sensing, the actin and 
microtubule cytoskeleton, and the classic Rho-ROCK pathway. This foundation of work has propelled us 
and others to determine if this pathway, which is known to control cell growth and survival, might also be 
responsible for drug resistance in stiff tumor environments.  For instance, Zustiak et al found that 
paclitaxel, a cytotoxic microtubule stabilizing agent, eliminated stiffness-induced drug resistance in most 
tested cell lines [30].  However, chemotherapies that induce apoptosis via non-cytoskeletal pathways, are 
also affected by substrate stiffness. Schrader et al. showed that stiff substrates reduced HCC cell 
apoptosis when treated with cisplatin, which causes apoptosis by crosslinking cellular DNA [29].  These 
studies motivated us to look at how stiffness might perturb the efficacy of a common chemotherapeutic 
within another class of drugs, specifically, sorafenib, a Raf kinase inhibitor that targets the Raf/MEK/ERK 
pathway. We also observed a clear stiffness-induced resistance to sorafenib across multiple cell lines. 
Consistent with Schrader et al., the HCC cell line (HEP3B) was the most stiffness-sensitive cell line 
tested, and showed a positive correlation between cell proliferation (at 24 hours) and drug resistance 
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(Suppl. Fig. 3A). However, cell proliferation did not correlate with drug resistance in any of the other cell 
lines tested, which were all from breast carcinoma; thus the simplest explanation for our results in Figure 
2, that cell proliferation on high stiffnesses was responsible for sorafenib resistance, does not hold. The 
IC-50s for most cell lines are higher on collagen-rich proteins than on basement membrane proteins, with 
the exception of the SkBr3 cell line, which has similar IC-50s on both protein mixtures (Figs. 2A-B). Yang 
et al. also found that binding of SkBr3 cells to laminin, which is a component in our basement membrane 
mixture, causes substantial resistance to anti-ErbB2 agents [11], possibly agreeing with our results in the 
SkBr3 cells. These results point to maximum possible sorafenib resistance in stiff, collagen-rich 
microenvironments, which represent highly progressed tumors. These results implicate tumor stiffening as 
a cause for the lack of success for sorafenib, which boasts a paltry 3-month survival increase in 
comparison to placebo in HCC [33]. 
Integrin binding can mediate cellular responses to substrate stiffness via RhoA activity, leading to 
stress fiber formation, focal adhesion assembly, actomyosin contractility, and cell spreading [37, 44, 45]. 
Although we did observe cell spread area changes in response to both stiffness and ECM protein (Figs. 
3A-D), we quantified no change in stiffness-induced resistance trend when co-administered sorafenib with 
ROCK inhibitor. Instead, we examined whether integrin-binding mediated this stiffness-induced drug 
response via some other pathway. β1 integrin has a high affinity for collagen [46], and increased signaling 
through β1 integrin binding protects cancer cells (MDA-MB-231 and MDA-MB-435) against paclitaxel [8] 
and small cell lung cancer cells against doxorubicin, cyclophosphamide, and etoposide [47]. Reducing β1 
integrin binding with an antibody sensitized the 231 cells to sorafenib, but did not affect the SkBr3s (Figs. 
3E-F). Park et al. also observed that SkBr3 cells were not responsive to β1 integrin inhibition as compared 
to MDA-MB-231, likely because of their inherently low β1 integrin expression [9].  
Ezzoukhry et al. observed that inhibiting EGFR sensitized several HCC cell lines to sorafenib 
treatment [38]; however, we found that co-treatment of a pharmacological EGFR inhibitor with sorafenib 
in both MDA-MB-231 and SkBr3 cells only affected sorafenib efficacy on soft gels (Figs. 3E-F). Given that 
integrin binding to the ECM can enhance EGFR phosphorylation in the absence of ligand binding [48], it 
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is possible that, at lower stiffnesses, β1 integrin predominantly mediates signaling through EGFR 
phosphorylation in the absence of ligand binding [49], but not at higher stiffness.   
 We found that JNK was the key mediator of sorafenib resistance on stiff substrates (Figs. 4-5). 
Activation of JNK has been reported to mediate either pro-apoptotic or anti-apoptotic signaling pathways 
depending on stimuli [50, 51], with parallel contradictory roles in vivo, either supporting tumor growth [52-
55] or suppressing tumorigenesis [56-59]. Our results indicate a role for JNK in enhancing cell survival 
during sorafenib treatment, and for the first time we show that JNK activation is regulated by substrate 
stiffness. The high activity of JNK on stiff substrates implicates high Rac1 activity and low RhoA activity 
[49, 60], and low RhoA activity is consistent with the overall lack of stress fiber formation observed in 231 
cells [61], regardless of stiffness (Fig. 3A). Further, ROCK inhibition did not affect the stiffness-induced 
drug resistance. Finally, RhoA/ROCK can activate ERK [32], and indirectly activates PI3K-Akt pathway 
[62], supporting our observations of a lack of stiffness-dependent ERK or Akt phosphorylation (Figs. 4A-
B). 
 Conversely, when we quantified phospho-protein activity in the presence of sorafenib and PDGF 
and EGF, we observed that ERK phosphorylation was higher on the stiff substrate.  This is consistent 
with other observations that cells on stiff substrates are more sensitive to EGF stimulation in comparison 
to those on soft substrates (Figs. 5A-B) [19, 23]. However, this transient ERK activation on stiff substrates 
did not prolong cell survival in the presence of sorafenib treatment (Fig. 5E). Combining both p38 and 
JNK inhibitors alongside sorafenib reversed the effect of inhibiting JNK alone, suggesting negative 
crosstalk between JNK and p38. Other studies have reported this antagonism between p38 and JNK 
before [63, 64]. We observed this same rescue of stiffness-mediated sorafenib resistance when we co-
administered JNK and ERK inhibitors, which is also supported by reports of JNK and ERK antagonism 
[65, 66]. 
Overall, these results elucidate a role for JNK in mediating resistance to sorafenib through β1 
integrin binding to collagen-rich environments (Fig. 6). β1 integrin activation leads to Src-mediated 
phosphorylation of EGFR [49, 67], which activates Ras/Raf/MEK/ERK and PI3K/Vav2/Rac1/JNK. 
Inhibiting EGFR improved the efficacy of sorafenib on soft gels (Fig. 3E), which we attribute to low β1 
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integrin affinity [49]. At high stiffness, however, EGFR inhibition had no effect, as integrin clustering 
increases, recruiting the FAK-Cas complex and activating Ras/Rac1/JNK [68-70]. 
In sum, the ability to capture the cell-matrix interactions present in the in vivo tumor 
microenvironment could profoundly influence our ability to understand true drug efficacy in vitro. Others 
have created similar high-throughput biomaterial platforms including ECM microarrays [71], contact-
printed microarrays [72], PEG microwells [73], and 2D biomaterials in 96-well plates [30, 41]. The most 
promising of these approaches have each used polyacryamide (PAA) gels, but require either a 
complicated plate insert [41], or manually placing gels into individual wells [30]. Our method of casting 
PEG-PC gels allowed us to quickly make multiple uniform gels of varying stiffnesses in multiple 96-well 
plates at the same time, and does not require fabrication of any special devices (Fig. 1). Our high-
throughput PEG-PC platform allowed us to identify β1 integrin, and its downstream effector, JNK, as 
mediators of tissue stiffening-induced drug resistance. Co-administering sorafenib with inhibitors to either 
of these targets equally eliminated stiffness-induced resistance in the 231 cells (Suppl. Fig. 4).  
5. Conclusion 
We propose that systems like our high-throughput PEG-PC hydrogel platform are critical for 
future screening of potential chemotherapeutics, as well as for discovery of possible mechanisms for 
failed efficacy of previously promising targets. With our platform, we discovered that the efficacy of 
sorafenib in carcinoma could potentially be increased by co-administering inhibitors to β1 integrin or JNK, 
which could not have been appreciated on traditional tissue culture plastic plates. Our results highlight the 
importance of incorporating relevant tissue stiffness and integrin binding ligands into the high-throughput 
drug screening process to increase the success of drugs in the development pipeline.  
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